CA2304000A1 - Antagoniste du recepteur de la vitronectine - Google Patents

Antagoniste du recepteur de la vitronectine Download PDF

Info

Publication number
CA2304000A1
CA2304000A1 CA002304000A CA2304000A CA2304000A1 CA 2304000 A1 CA2304000 A1 CA 2304000A1 CA 002304000 A CA002304000 A CA 002304000A CA 2304000 A CA2304000 A CA 2304000A CA 2304000 A1 CA2304000 A1 CA 2304000A1
Authority
CA
Canada
Prior art keywords
compound
cells
compound according
medicament
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002304000A
Other languages
English (en)
Inventor
William E. Bondinell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2304000A1 publication Critical patent/CA2304000A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention porte sur un composé de formule (I) qui est un antagoniste du récepteur de la vitronectine et qui est utile dans le traitement de l'ostéoporose, ou sur un sel de celui-ci, acceptable en pharmacie.
CA002304000A 1997-09-24 1998-09-24 Antagoniste du recepteur de la vitronectine Abandoned CA2304000A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5986797P 1997-09-24 1997-09-24
US60/059,867 1997-09-24
PCT/US1998/019987 WO1999015178A1 (fr) 1997-09-24 1998-09-24 Antagoniste du recepteur de la vitronectine

Publications (1)

Publication Number Publication Date
CA2304000A1 true CA2304000A1 (fr) 1999-04-01

Family

ID=22025805

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002304000A Abandoned CA2304000A1 (fr) 1997-09-24 1998-09-24 Antagoniste du recepteur de la vitronectine

Country Status (13)

Country Link
EP (1) EP1023073A1 (fr)
JP (1) JP2002500162A (fr)
KR (1) KR20010024249A (fr)
CN (1) CN1271284A (fr)
AU (1) AU9578798A (fr)
BR (1) BR9813214A (fr)
CA (1) CA2304000A1 (fr)
HU (1) HUP0003931A2 (fr)
IL (1) IL135188A0 (fr)
NO (1) NO20001515D0 (fr)
PL (1) PL339414A1 (fr)
TR (1) TR200000786T2 (fr)
WO (1) WO1999015178A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1150965A4 (fr) 1999-02-03 2002-05-15 Merck & Co Inc Derives de la benzazepine utilises comme antagonistes du recepteur alpha-v de l'integrine
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
EP1381384B1 (fr) 2001-04-24 2011-05-25 Merck Patent GmbH POLYTHERAPIE A BASE D'AGENTS ANTIANGIOGENIQUES ET DE FACTEUR DE NECROSE TUMORALE TNFalpha
WO2003059251A2 (fr) 2001-10-22 2003-07-24 The Scripps Research Institute Composes de ciblage d'anticorps
EP1628949A4 (fr) 2003-04-04 2008-07-02 Smithkline Beecham Corp Procede et produits intermediaires pour preparer des benzazepines
CA2554644C (fr) 2004-02-02 2015-06-16 Pioneer Hi-Bred International, Inc. Facteur de transcription odp2 (ovule development protein 2) du domaine ap2 et procedes pour l'utiliser
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
EP2335733B1 (fr) 2006-01-18 2014-08-06 Merck Patent GmbH Thérapie spécifique utilisant des ligands d'intégrine pour traiter le cancer
CN101588812A (zh) 2007-01-18 2009-11-25 默克专利有限公司 使用整联蛋白配体治疗癌的特异疗法和药物
CA2705916C (fr) 2007-11-16 2016-01-05 Ube Industries, Ltd. Compose de benzazepinone
WO2009111679A2 (fr) * 2008-03-06 2009-09-11 Smithkline Beecham Corporation Procédé
WO2010093706A2 (fr) 2009-02-10 2010-08-19 The Scripps Research Institute Vaccination programmée chimiquement
US20120095215A1 (en) 2009-03-30 2012-04-19 Ube Industries, Ltd. Medical composition for treatment or prophylaxis of eye diseases
WO2010136168A2 (fr) 2009-05-25 2010-12-02 Merck Patent Gmbh Administration continue de ligands d'intégrines pour le traitement du cancer
AU2010339404B2 (en) 2009-12-30 2016-01-28 Pioneer Hi-Bred International, Inc. Methods and compositions for the introduction and regulated expression of genes in plants
AU2010339481B2 (en) 2009-12-30 2016-02-04 Pioneer Hi-Bred International, Inc. Methods and compositions for targeted polynucleotide modification
EP3148587B1 (fr) 2014-05-30 2021-02-24 Pfizer Inc Dérivés carbonitriles en tant que modulateurs sélectifs du récepteur des androgènes
WO2023275715A1 (fr) 2021-06-30 2023-01-05 Pfizer Inc. Métabolites de modulateurs sélectifs du récepteur des androgènes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA60311C2 (uk) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція

Also Published As

Publication number Publication date
HUP0003931A2 (hu) 2001-10-28
JP2002500162A (ja) 2002-01-08
WO1999015178A1 (fr) 1999-04-01
PL339414A1 (en) 2000-12-18
CN1271284A (zh) 2000-10-25
KR20010024249A (ko) 2001-03-26
EP1023073A1 (fr) 2000-08-02
NO20001515L (no) 2000-03-23
NO20001515D0 (no) 2000-03-23
AU9578798A (en) 1999-04-12
IL135188A0 (en) 2001-05-20
TR200000786T2 (tr) 2000-08-21
BR9813214A (pt) 2000-08-29

Similar Documents

Publication Publication Date Title
AU733417B2 (en) Vitronectin receptor antagonists
CA2304000A1 (fr) Antagoniste du recepteur de la vitronectine
WO1999015170A1 (fr) Antagoniste du recepteur de vitronectine
AU738433B2 (en) Vitronectin receptor antagonists
US6495560B1 (en) Vitronectin receptor antagonist
US20020019387A1 (en) Vitronectin receptor antagonist
EP1102587A2 (fr) Antagonistes du recepteur de la proteine s
US20020128257A1 (en) Vitronectin receptor antagonist
US6576643B2 (en) Vitronectin receptor antagonists
MXPA00002895A (en) Vitronectin receptor antagonist
CZ20001061A3 (cs) Antagonista receptoru pro vitronektin
MXPA00002896A (en) Vitronectin receptor antagonist
CZ20001060A3 (cs) Antagonista receptoru vitronektinu
CZ2000979A3 (cs) Antagonista vitronektinového receptoru

Legal Events

Date Code Title Description
FZDE Discontinued